Check-Cap Ltd. – Consensus Indicates Potential 6.7% Upside

Broker Ratings

Check-Cap Ltd. with ticker code (CHEK) have now 2 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The target price ranges between 2 and 1.5 calculating the average target price we see 1.75. Now with the previous closing price of 1.64 this would indicate that there is a potential upside of 6.7%. The 50 day MA is 0.63 and the 200 day moving average is 0.48. The market cap for the company is $73m. Visit the company website at: http://www.check-cap.com

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based system that utilizes low-dose X-rays for screening of the colon to detect polyps, masses, and colorectal cancers in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule, which is designed to measure, collect, and transmit structural information; C-Scan Track, a biocompatible unit worn on the patient’s back for capsule control, tracking, and data recording; and C-Scan View, a personal computer-based software package, which is designed to retrieve and process clinical data from the C-Scan Track, and to reconstruct and produce 3D visualization of the colon’s inner surface. The company was founded in 2004 and is based in Isfiya, Israel.

Share on Stocktwits

Good news travels fast (but only if you make that happen):

Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on facebook
Facebook
Share on email
Email
Share on whatsapp
WhatsApp